Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Net Margin: 2021-2025

Historic Net Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to 10.19%.

  • Kiniksa Pharmaceuticals International's Net Margin rose 2150.00% to 10.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.01%, marking a year-over-year increase of 2776.00%. This contributed to the annual value of -10.21% for FY2024, which is 1214.00% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Net Margin stood at 10.19%, which was down 10.37% from 11.37% recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Net Margin peaked at 226.05% during Q3 2022, and registered a low of -252.53% during Q3 2021.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Net Margin had a median value of -7.25% in 2024 and averaged -9.16%.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Net Margin spiked by 47,858bps in 2022 and then slumped by 24,671bps in 2023.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's Net Margin stood at -235.15% in 2021, then skyrocketed by 17,545bps to -59.70% in 2022, then skyrocketed by 65bps to -59.05% in 2023, then soared by 5,180bps to -7.25% in 2024, then soared by 2,150bps to 10.19% in 2025.
  • Its Net Margin stands at 10.19% for Q3 2025, versus 11.37% for Q2 2025 and 6.20% for Q1 2025.